Brucellosis Market research report– by species (Brucella suis, B. abortus, B. melitensis), Diagnosis (serological tests, molecular techniques, bone marrow biopsy, CT, MRI), Treatment (vaccine, antibiotics), End user– Forecast till 2032.

Brucellosis Market Scenario:

The Brucellosis Market is expected to reach USD 0.63 Billion by 2032 at 8.9% CAGR during the forecast period 2023-2032.Brucellosis is a bacterial infection that spreads from animals to people most often via unpasteurized milk, cheese and other dairy products. More rarely, the bacteria that cause brucellosis can spread through the air or through direct contact with infected animals. The infection can usually be treated successfully with antibiotics. Avoiding unpasteurized dairy products and taking precautions while working with animals or in pathogy laboratories may prevent brucellosis. The global burden of human brucellosis remains enormous as the organism causes more than 500,000 infections per year worldwide. Usually, brucellosis is more common in males than in females and are generally non occuring in infants.

Brucella are small aerobic intracellular organisms which localize in the reproductive organs of host animals, causing abortions and sterility. They usually spread through fliuds such as animal’s urine, milk, placental fluid, and others. To this day, 8 species have been identified, named primarily for the source animal or features of infection. Out of these, four species are significantly pathogenous to humans, these include Brucella melitensis (sheep, goats), Brucella suis (swine), Brucella abortus (buffalos, bison), Brucella canis (dogs)

In the U.S., the Nationwide eradication of brucellosis from domestic cattle and bison are carried out by governing bodies such as USDA, APHIS, Cooperative State Federal Program. Currently all 50 states as well as Puerto Rico and the U.S. Virgin Islands are brucellosis free. Any livestock market that has been approved by the State is handled under the supervision of the Cooperative State–Federal Brucellosis Eradication Program.

A Brucella abortus product that is approved by the Brucellosis Eradication Program and licensed under USDA for injection into cattle to enhance their resistance to brucellosis. The brucellosis vaccine is called RB51. Pasteurization has been proven to destroy the causative agent of Brucellosis. 

• Brucellosis Vaccine Suppliers


• Brucellosis Drug Manufacturers


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Academic Medical Institutes and Universities

Segmentation:

The brucellosis market is segmented on the basis of species, diagnosis,  treatment and end-users.

On the basis of species, the brucellosis market is segmented into Brucella suis, Brucella abortus, Brucella melitensis, Brucella canis and others 

On the basis of diagnosis, brucellosis market is segmented into serological tests, molecular techniques, bone marrow biopsy, X-rays, computerized tomography (CT), magnetic resonance imaging (MRI), cerebrospinal fluid culture, echocardiography and others. The serological tests is segmented into serum agglutination test, rose bengal test, lateral flow assay, compliment fixation test, coombs test, enzyme linked immuno sorbent assaym, and immunocapture-agglutination test (brucellacapt). The molecular techniques is segmented into Polymerase Chain Reaction (PCR), Loop- mediated isothermal amplification assay, Multiple Locus VNTR Analysis (MLVA) typing. The Polymerase Chain Reaction (PCR) is further classified into standard PCR, real time PCR, nested PCR, PCR based assays

On the basis of treatment, brucellosis market is segmented into antibiotics, vaccines, and others

On the basis of end-user, the brucellosis market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.

Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation

Regional Analysis:

The brucellosis market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

The European brucellosis market is the largest market owing to the high investment in various private and government funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.

America is projected to hold the second largest share of the brucellosis market as due to the eradication of these disease from the USA. Currently, fewer than 100 cases are reported annually to the Centers for Disease Control and Prevention (CDC) with approximately 60% of human brucellosis cases in the United States now occur in California and Texas.  Brucellosis has become rare in North America due to numerous veterinary control measures such as routine screening and vaccination of domestic livestock. Most cases of brucella infection in the U.S. is due to the consumption of imported unpasteurized dairy products from Mexico.

The Asia Pacific and the Middle Eastern region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector. The heaviest disease burden lies in countries of the Mediterranean basin and Arabian Peninsula, and the disease is also common in India, Mexico, and South & Central America. In Africa, incidence rates of 1.2-70 cases per 100,000 people have been reported. In Africa, such endemic diseases are controlled through animal slaughter due to the fragile nature of the food supply.

Key Players

Some of key the players in the brucellosis market are Hester Biosciences Limited, ATA FEN Inc., Biogénesis-Bagó S.A., Biopharma, Biovet, Calier & Biologicos Laverlam, Merck Animal Health (MSD Animal Health), Colorado Serum Company, Indian Immunologicals Limited, Dollvet, Veterinary Technologies Corporation, China Animal Husbandry Co., Ltd. (CAHIC), LABIOFAM, BCG Vaccine Laboratory, and others.